Inhibition of FLT3-ITD-expressing AML cells with FLT3 kinase inhibitors, such as midostaurin, quizartinib, gilteritinib, sorafenib or crenolanib, has been shown to be effective in clinical trials to induce and extend remissions; however, many patients ultimately become resistant to TKI treatment. This evidence concerns the gene FLT3 and acute myeloid leukemia.